Arsanis Out-Licenses Preclinical Stage E. coli Monoclonal Antibodies
04 April 2018 - 2:00PM
Business Wire
Transaction provides potential for further
development of novel mAbs while allowing Arsanis to continue to
focus its resources on ongoing Phase 2 clinical trial of lead
product candidate ASN100
Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical
company focused on applying monoclonal antibody immunotherapies to
address serious infectious diseases, today announced that it has
entered into an agreement under which BB100, LLC has secured an
exclusive, worldwide preclinical development license, and an option
to a clinical development and commercialization license, to
monoclonal antibodies (mAbs) targeting E. coli that were discovered
by Arsanis in its ASN200 program.
“This transaction allows Arsanis to continue the focused
execution of our ongoing ASN100 Phase 2 clinical trial while
providing for the potential advancement of our novel, multi-modal
mAbs targeting E. coli, a leading cause of serious hospital
infections,” said René Russo, chief executive officer of Arsanis.
“We are pleased to place these mAbs in the hands of BB100, a
subsidiary of Bravos Bioscience, LLC, led by Dr. Paul Ambrose and a
leadership team that is globally recognized as a leader in
anti-infective drug development and has played a critical role in
the development and approval of many anti-infectives developed over
the last decade.”
Under the agreement, Arsanis has granted BB100 the exclusive
right to conduct further preclinical development activities on
licensed mAbs, with an option to enter into an exclusive global
development and commercial license.
About ASN200The ASN200 program is currently in
preclinical development. Within this program, Arsanis discovered a
unique monoclonal antibody, ASN-4, that has multiple modes of
action against the hyper-virulent, multi-drug resistant E.
coli ST131-O25b:H4 clone. ASN-4 is directly bactericidal and
provides anti-inflammatory effects without the need for innate
immune cells and therefore, has the potential to be beneficial even
in immunocompromised patients. In addition, ASN-4 has been
demonstrated to potentiate the activity of antibiotics, potentially
minimizing the use of last-line antibiotics with less favorable
toxicity profiles. ASN-4 is highly potent and elicits a high level
of protection at very low doses in relevant animal models and
therefore has the potential to be used both for prevention of
disease in colonized, high-risk patients and treatment of patients
with serious infections, including those in whom antibiotics have
failed.
About BB100BB100 is a fully owned subsidiary of Bravos
Biosciences, LLC. Paul G. Ambrose, Pharm.D.,
F.I.D.S.A., currently serves as president of the Institute for
Clinical Pharmacodynamics (ICPD, Schenectady, NY). Both Bravos
Biosciences and ICPD are cofounded by Drs. Ambrose, Sujata M.
Bhavnani and Christopher M. Rubino. The team’s areas of scientific
inquiry primarily involve anti-infective translational science,
with the goal of improving patient care through the application of
pharmacokinetic-pharmacodynamic (PK-PD) principles. Dr. Ambrose has
held academic appointments at the University of Oxford and the
University at Buffalo as well as past industry positions including
at Bristol Myers Squibb. Dr. Ambrose holds a Pharm.D. from the
University of the Pacific and completed a Post-Doctoral Fellowship
in infectious diseases at Hartford Hospital.
About ArsanisArsanis, Inc. is a clinical-stage
biopharmaceutical company focused on applying monoclonal antibody
(mAb) immunotherapies to address serious infectious diseases. A
deep understanding of the pathogenesis of infection, paired with
access to what the company believes to be some of the most advanced
mAb discovery techniques and platforms available today, has
positioned Arsanis to further its goal of building and
advancing a pipeline of novel mAbs with multiple mechanisms of
action and high potency against their intended targets. The
company’s lead clinical program, ASN100, is aimed at serious
Staphylococcus aureus infections and is being evaluated in a
Phase 2 clinical trial for the prevention of S.
aureus pneumonia in high-risk, mechanically ventilated
patients. In addition to ASN100, its preclinical pipeline is
comprised of mAbs targeting multiple serious bacterial and viral
pathogens, including respiratory syncytial virus.
Arsanis is a U.S. company headquartered in Waltham,
Massachusetts, with European research and preclinical development
operations headquartered in Vienna, Austria (Arsanis
Biosciences GmbH).
For more information, please visit the Arsanis website at
www.arsanis.com.
Cautionary Note Regarding Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include those regarding Arsanis’
plans, strategies and expectations for the clinical development of
its mAb programs; the expected benefits of the option and license
agreement for ASN200; and the potential benefit of its strategic
plans and focus. The words “anticipate,” “believe,” “estimate,”
“expect,” “intend,” “may,” “plan,” “predict,” “project,” “would,”
“could,” “potential,” “possible,” “hope,” “strategy,” “milestone,”
“will,” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Such statements are
subject to numerous important factors, risks and uncertainties that
may cause actual events or results to differ materially from
Arsanis' current expectations and beliefs. For example, there can
be no guarantee that any mAb programs Arsanis is developing will
successfully commence or complete necessary preclinical and
clinical development phases, or that development of any of Arsanis'
product candidates will successfully continue. There can be no
guarantee that any positive developments in Arsanis' business will
result in stock price appreciation. Management's expectations and,
therefore, any forward-looking statements in this press release
could also be affected by risks and uncertainties relating to a
number of other important factors, including: Arsanis' results of
clinical trials and preclinical studies, including subsequent
analysis of existing data and new data received from ongoing and
future studies; the content and timing of decisions made by the
U.S. FDA and other regulatory authorities, investigational review
boards at clinical trial sites and publication review bodies;
Arsanis' ability to obtain and maintain requisite regulatory
approvals and to enroll patients in its planned and ongoing
clinical trials; unplanned cash requirements and expenditures;
competitive factors; Arsanis' ability to obtain, maintain and
enforce patent and other intellectual property protection for any
product candidates it is developing; Arsanis' ability to maintain
key collaborations; and general economic and market conditions.
These and other risks are described in greater detail under the
caption "Risk Factors" included in Arsanis’ public filings with the
Securities and Exchange Commission. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and Arsanis expressly disclaims any obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180404005315/en/
Media Contact:Ten Bridge CommunicationsKrystle Gibbs,
508-479-6358krystle@tenbridgecommunications.comorInvestor
Contact:Michael Gray, 781-819-5201Chief Operating and Chief
Financial Officermike.gray@arsanis.com
Actelis Networks (NASDAQ:ASNS)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Actelis Networks (NASDAQ:ASNS)
Historical Stock Chart
Von Jul 2023 bis Jul 2024